ARX788 possible new drug after t-dm1, t-dxd, tucatinib
 

ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive (INTERIM) Results

https://www.businesswire.com/news/ho...sitive-Results

Emerging Data Behind 2 Antibody Drug Conjugates for Breast and

https://www.targetedonc.com/view/eme...rostate-cancer

"...
This trial is a phase 2 study evaluating ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.
..."